N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: Strategies to eliminate reactive metabolites
Sajiv K. Nair(Pfizer (United States)), Deepak Dalvie(Pfizer (United States)), Natilie Hosea(University of British Columbia), Sue Zhou(Pfizer (United States)), Jennifer E. Vogel(Pfizer (United States)), Hengmiao Cheng(Pfizer (United States)), Stanley Kupchinsky(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Arturo Castro(Pfizer (United States)), Jean Matthews(Pfizer (United States)), Theodore Johnson(Pfizer (United States)), Ping Kang(University of British Columbia), Stephan J. Cripps(Pfizer (United States)), Andrea Fanjul(Pfizer (United States)), Klaus Dress(Pfizer (United States)), Jacques Ermolieff(Pfizer (United States)), Paul A. Rejto(Pfizer (United States)), Yong Wang(Dalian Medical University), Christopher Smith(Pfizer (United States)), Jacqui Hoffman(Pfizer (United States)), Michael Siu(University of California San Diego), Wendy Taylor(Pfizer (United States)), Amy LaPaglia(Pfizer (United States))
Cited by 11
Related Papers
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
|Nature Genetics|2014|1.1k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
|Nature Genetics|2011|775
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382